Baltimore, Maryland 21201


Purpose:

The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.


Study summary:

Primary - - To compare the safety profile of a single intravenous administration of FGI-101-1A6 as compared with Placebo Secondary - To evaluate the pharmacokinetics (PK) of a singel intravenous administration of FGI-101-1A6 - To evaluate the immunogenicity of FGI-101-1A6


Criteria:

Inclusion Criteria: - Healthy volunteers ages 18-45 - Normal laboratory (blood tests) results Exclusion Criteria: - Prior immunization with live-attenuated vaccines


NCT ID:

NCT01299142


Primary Contact:

Melinda Roberson
Phone: 410-706-8877
Email: mroberson@snbl-pc.com


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21201
United States

Roberson
Email: mroberson@snbl-pc.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.